Biologic Agents for the Treatment of Severe Eosinophilic Asthma: A Systematic Review

Abstract

Introduction: Severe eosinophilic asthma is a phenotype characterized by persistent symptoms and exacerbations despite high-dose inhaled corticosteroids. Biologic therapies targeting the IL-5 pathway (mepolizumab, reslizumab, benralizumab) and the IL-4/IL-13 pathway (dupilumab) have been developed for this population.

Methods: A systematic search was performed for placebo-controlled RCTs of licensed biologics in patients with severe eosinophilic asthma. The primary outcomes were the rate of severe exacerbations and change in pre-bronchodilator FEV1.

Results: The meta-analysis included 25 RCTs. All reviewed biologics significantly reduced the annual rate of severe exacerbations by approximately 50-70% compared to placebo. They also produced clinically meaningful improvements in FEV1, asthma control scores, and quality of life, while allowing for a reduction in oral corticosteroid use.

Discussion: These biologics effectively target the underlying type 2 inflammation that drives severe eosinophilic asthma. The choice of agent may be guided by factors such as dosing frequency, route of administration, and specific patient characteristics.

Conclusion: Biologic therapies are highly effective in reducing exacerbations and improving lung function in patients with severe eosinophilic asthma.